Search Results

You are looking at 181 - 190 of 1,257 items for :

  • Refine by Access: All x
Clear All
Full access

Mohamedtaki A. Tejani, Anna ter Veer, Dana Milne, Rebecca Ottesen, Tanios Bekaii-Saab, Al B. Benson III, Deborah Schrag, Stephen Shibata, John Skibber, Martin Weiser, Neal Wilkinson, and Steven J. Cohen

mucinous appendiceal adenocarcinomas (when surgery is not a viable option) has not been established. Several retrospective analyses 4 - 6 failed to show a significant benefit from systemic chemotherapy. However, these were small series that did not

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

local disease with surgery, radiation therapy, or both, and systemic treatment with chemotherapy, endocrine therapy, biologic therapy, or combinations of these. The need for and selection of various local or systemic therapies are based on several

Full access

Noam VanderWalde, Reshma Jagsi, Efrat Dotan, Joel Baumgartner, Ilene S. Browner, Peggy Burhenn, Harvey Jay Cohen, Barish H. Edil, Beatrice Edwards, Martine Extermann, Apar Kishor P. Ganti, Cary Gross, Joleen Hubbard, Nancy L. Keating, Beatriz Korc-Grodzicki, June M. McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O'Connor, Hope S. Rugo, Randall W. Rupper, Dale Shepard, Rebecca A. Silliman, Derek L. Stirewalt, William P. Tew, Louise C. Walter, Tanya Wildes, Mary Anne Bergman, Hema Sundar, and Arti Hurria

to anticancer therapy. Nevertheless, advanced age alone should not be the only criteria to preclude effective treatment that could improve quality of life or lead to a survival benefit in older patients. 6 , 7 Surgery, radiation therapy (RT

Full access

Ania Syrowatka, James A. Hanley, Daniala L. Weir, William G. Dixon, Ari N. Meguerditchian, and Robyn Tamblyn

vary based on the period of cancer care, specifically during hospital-based treatment (ie, treatments received within a hospital on either an inpatient or outpatient basis, specifically breast cancer surgery, chemotherapy, and/or radiation) and

Full access

Urshila Durani, Dennis Asante, Thorvardur Halfdanarson, Herbert C. Heien, Lindsey Sangaralingham, Carrie A. Thompson, Prema Peethambaram, Fernando J. Quevedo, and Ronald S. Go

staging period was defined as 60 days before to 60 days after surgery. The surveillance period was from 60 days after surgery until death or last follow-up. “High use” in the surveillance cohort was defined as >2 CT, PET, or PET/CT scans in 1 year, based

Full access

Vlad Sandulache, Anita Sabichi, George Chen, and Scott Charnitsky

generate baseline data (2000–2010) for: (1) time to treatment (surgery, 24 days; radiation, 48 days) and (2) treatment package time <100 days compliance (68%). We developed a tool available to providers and clinic staff to prospectively track patients from

Full access

Yifan Wang, Adeline Cuggia, Yen-I Chen, Josée Parent, Agatha Stanek, Robert E. Denroche, Amy Zhang, Robert C. Grant, Céline Domecq, Bryn Golesworthy, Chaya Shwaartz, Ayelet Borgida, Spring Holter, Julie M. Wilson, George Chong, Grainne M. O’Kane, Jennifer J. Knox, Sandra E. Fischer, Steven Gallinger, Zu-Hua Gao, William D. Foulkes, Kevin A. Waschke, and George Zogopoulos

66 years, this BD-IPMN progressed in size with interval development of nodularity ( Figure 2C, D ). A completion pancreatectomy was recommended, but the patient declined surgery. In the subsequent 6 months, the BD-IPMN progressed to a large

Full access

Margaret von Mehren, R. Lor Randall, Robert S. Benjamin, Sarah Boles, Marilyn M. Bui, Ernest U. Conrad III, Kristen N. Ganjoo, Suzanne George, Ricardo J. Gonzalez, Martin J. Heslin, John M. Kane III, Henry Koon, Joel Mayerson, Martin McCarter, Sean V. McGarry, Christian Meyer, Richard J. O'Donnell, Alberto S. Pappo, I. Benjamin Paz, Ivy A. Petersen, John D. Pfeifer, Richard F. Riedel, Scott Schuetze, Karen D. Schupak, Herbert S. Schwartz, William D. Tap, Jeffrey D. Wayne, Mary Anne Bergman, and Jillian Scavone

, positive family history for desmoid tumors, abdominal surgery, and the APC mutation site were identified as significant risk factors for the development of desmoid tumors. 25 The median age at diagnosis was 31 years, with most desmoid tumors arising in

Full access

Emily Chan, Paul E. Wise, and A. Bapsi Chakravarthy

performed to rule out synchronous primaries in the colon or rectum. If obstruction precludes this at initial evaluation, it should be performed before definitive surgery to determine the type of surgery required. If full endoscopic evaluation is not

Full access

Clayton A. Smith and Lisa A. Kachnic

, historical rates of local failure following surgery alone using older techniques were ≥25%. 2 The development of total mesorectal excision (TME) with sharp dissection of mesorectal contents further reduced the rates of local recurrence to as low as 8%. 3